Form 4 Filing for George Simeon

George Simeon, a director at CRISPR Therapeutics AG, was granted 13,000 stock options on June 5, 2026. These options, exercisable at $51.84 per share, are set to vest in 12 equal monthly installments starting June 30, 2026, contingent upon continued service. The options will fully vest by June 5, 2036, or the 2027 Annual Meeting, whichever comes first. The filing also notes that Simeon acquired these options under a compensatory plan, with a transaction code indicating an acquisition. Following the transaction, Simeon holds 13,000 shares underlying these options.